Eisai and Biogen announced that the US Food and Drug Administration (FDA) will process as a matter of priority an application for the marketing of lecanemab, an anti-beta-amyloid antibody. The Agency has indicated 6 January next year as the target date for the publica...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
